{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:59:59Z","timestamp":1791046799209,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.bbapap.2009.11.008","type":"journal-article","created":{"date-parts":[[2009,11,16]],"date-time":"2009-11-16T09:46:09Z","timestamp":1258364769000},"page":"445-453","source":"Crossref","is-referenced-by-count":186,"title":["Extended kinase profile and properties of the protein kinase inhibitor nilotinib"],"prefix":"10.1016","volume":"1804","author":[{"given":"Paul W.","family":"Manley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Drueckes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Fendrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Furet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Liebetanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Martiny-Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Mestan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriano","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2009.11.008_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and BCR-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cell.2008.07.047","article-title":"Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation","volume":"134","author":"Filippakopoulos","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bbapap.2009.11.008_bib3","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","article-title":"Charting the molecular network of the drug target Bcr-Abl","volume":"106","author":"Brehme","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbapap.2009.11.008_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbapap.2009.11.008_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2009.11.008_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib","volume":"599","author":"Day","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbapap.2009.11.008_bib8","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib9","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2009.11.008_bib10","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase\u2013inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2009.11.008_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389557043487321","article-title":"Bcr-Abl kinase mutations and drug resistance to imatinib (STI571) in chronic myelogenous leukemia","volume":"4","author":"Cowan-Jacob","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bbapap.2009.11.008_bib12","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","article-title":"Urea-derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases","volume":"14","author":"Manley","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbapap.2009.11.008_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"AMN107: characterization of a novel inhibitor of both wild-type and imatinib-resistant mutant Bcr-Abl in vitro and in murine models of leukemia","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbapap.2009.11.008_bib14","first-page":"80","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"D63","author":"Cowan-Jacob","year":"2007","journal-title":"Acta Cryst."},{"key":"10.1016\/j.bbapap.2009.11.008_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1371\/journal.pbio.0040144","article-title":"A Src-like inactive conformation in the Abl tyrosine kinase domain","volume":"4","author":"Levinson","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib16","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2009.11.008_bib17","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":", AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbapap.2009.11.008_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl","volume":"21","author":"Eck","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/17460441.3.1.115","article-title":"Developing assays for kinase drug discovery\u2014where have the advances come from?","volume":"3","author":"Vogel","year":"2008","journal-title":"Exp. Opin. Drug Discov."},{"key":"10.1016\/j.bbapap.2009.11.008_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ddmec.2005.05.027","article-title":"Harnessing the power of fireflies and mice for assessing cancer mechanisms","volume":"2","author":"Kung","year":"2005","journal-title":"Drug Discov. Today: Disease Mechanisms"},{"key":"10.1016\/j.bbapap.2009.11.008_bib21","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","article-title":"The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR\u03b2 and FIP1L1-PDGFR\u03b1 in vitro and in vivo","volume":"106","author":"Stover","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2009.11.008_bib22","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1053\/j.gastro.2006.09.017","article-title":"Effects of PKC412, nilotinib and imatinib against GIST-associated PDGFRA mutants conferring differential sensitivity to imatinib","volume":"131","author":"Weisberg","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbapap.2009.11.008_bib23","unstructured":"C. Cullinane, A. Natoli, Y. Hui, N. Conus, J. Brueggen, P.W. Manley, G.A. McArthur, Characterization of the activity of nilotinib against a model of KIT-induced neoplasia using FDG-PET, in Proc of 99th annual meeting of Amer Assoc Cancer Res; 2008 Apr 12-16; San Diego, CA; Philadelphia (PAA); AACR; 2008."},{"key":"10.1016\/j.bbapap.2009.11.008_bib24","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.0511292103","article-title":"An efficient rapid system for profiling the cellular activities of molecular libraries","volume":"103","author":"Melnick","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbapap.2009.11.008_bib25","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","article-title":"Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210bcr\/abl protein","volume":"85","author":"Daley","year":"1988","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbapap.2009.11.008_bib26","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1110\/ps.051750905","article-title":"High yield bacterial expression of active c-Abl and c-Src tyrosine kinases","volume":"14","author":"Seeliger","year":"2005","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbapap.2009.11.008_bib27","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1073\/pnas.0600048103","article-title":"Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase","volume":"103","author":"Wang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbapap.2009.11.008_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib30","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/clinchem\/41.9.1391","article-title":"Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer","volume":"41","author":"Mathis","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbapap.2009.11.008_bib31","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2009.11.008_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.str.2007.01.015","article-title":"c-Src binds to the cancer drug imatinib with an inactive Abl\/c-Kit conformation and a distributed thermodynamic penalty","volume":"15","author":"Seeliger","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.bbapap.2009.11.008_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1006\/bbrc.1997.6812","article-title":"Expression of a kinase-defective Eph-like receptor in the normal human brain","volume":"235","author":"Matsuoka","year":"1997","journal-title":"Biochim. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2009.11.008_bib34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/anie.200502770","article-title":"NMR characterization of kinase p38 dynamics in free and ligand-bound forms","volume":"45","author":"Vogtherr","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbapap.2009.11.008_bib35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/0008-5472.CAN-07-2404","article-title":"Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib","volume":"68","author":"Gilmer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbapap.2009.11.008_bib36","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.chembiol.2008.09.007","article-title":"Small molecule recognition of c-Src via the imatinib-binding conformation","volume":"15","author":"Dar","year":"2008","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib37","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1021\/jm8010299","article-title":"Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states","volume":"51","author":"Kufareva","year":"2008","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.bbapap.2009.11.008_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0263-7855(90)80070-V","article-title":"WHAT IF: a molecular modeling and drug design program","volume":"8","author":"Vriend","year":"1990","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.bbapap.2009.11.008_bib39","doi-asserted-by":"crossref","first-page":"19298","DOI":"10.1074\/jbc.M413059200","article-title":"Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an Aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA","volume":"280","author":"Wang","year":"2005","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.bbapap.2009.11.008_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11010-008-0021-1","article-title":"ZAK induces MMP-2 activity via JNK\/p38 signals and reduces MMP-9 activity by increasing TIMP-1\/2 expression in H9c2 cardiomyoblast cells","volume":"325","author":"Cheng","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbapap.2009.11.008_bib41","first-page":"16","article-title":"RhoGDI\u03b2-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAK","author":"Huang","year":"2009","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bbapap.2009.11.008_bib42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/path.2322","article-title":"Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo","volume":"214","author":"Eisenberger","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbapap.2009.11.008_bib43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2009.11.008_bib44","doi-asserted-by":"crossref","unstructured":"C. Tanaka, O. Yin, V. Sethuraman, T. Smith, X.F. Wang, K. Grouss, H. Kantarjian, F. Giles, O.G. Ottmann, L. Galitz, H. Schran, Clinical Pharmacokinetics of Nilotinib, Clin. Pharmacol. Ther. (2009), doi:10.1038\/clpt.2009.208.","DOI":"10.1038\/clpt.2009.208"},{"key":"10.1016\/j.bbapap.2009.11.008_bib45","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2009.11.008_bib46","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"Le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2009.11.008_bib47","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.bmcl.2009.06.002","article-title":"The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian a-carbonic anhydrase isoforms","volume":"19","author":"Parkkila","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbapap.2009.11.008_bib48","unstructured":"P.W. Manley, J. Br\u00fcggen, D. Fabbro, G. Martiny-Baron, J. Mestan, T. Meyer, Extended kinase profiling of the BCR-ABL inhibitor nilotinib, in Proc of 100th annual meeting of Amer Assoc Cancer Res; 2007 Apr 14\u201318; Los Angeles, CA; Philadelphia (PAA); AACR; 2007."},{"key":"10.1016\/j.bbapap.2009.11.008_bib49","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1158\/1078-0432.CCR-07-1984","article-title":"Molecular characterization of pediatric gastrointestinal stromal tumors","volume":"14","author":"Agaram","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbapap.2009.11.008_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.22681","article-title":"L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition","volume":"121","author":"Antonescu","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbapap.2009.11.008_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.leu.2404944","article-title":"Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis","volume":"22","author":"Brownlow","year":"2008","journal-title":"Leukemia"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963909003410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963909003410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T17:43:08Z","timestamp":1590255788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963909003410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1570963909003410"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2009.11.008","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}